Changes in Serum Cytokines May Predict Therapeutic Efficacy of Tofacitinib in Rheumatoid Arthritis

Objective. Tofacitinib is a novel therapy for rheumatoid arthritis (RA). The aim of this study was to measure various serum cytokines levels and to explore potential markers predictive of therapeutic efficacy of tofacitinib for RA patients. Methods. Thirty-two patients with RA were given tofacitinib...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuxuan Li, Lin Yuan, Jie Yang, Yue Lei, Hui Zhang, Liping Xia, Hui Shen, Jing Lu
Format: Article
Language:English
Published: Wiley 2019-01-01
Series:Mediators of Inflammation
Online Access:http://dx.doi.org/10.1155/2019/5617431
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832564767856787456
author Yuxuan Li
Lin Yuan
Jie Yang
Yue Lei
Hui Zhang
Liping Xia
Hui Shen
Jing Lu
author_facet Yuxuan Li
Lin Yuan
Jie Yang
Yue Lei
Hui Zhang
Liping Xia
Hui Shen
Jing Lu
author_sort Yuxuan Li
collection DOAJ
description Objective. Tofacitinib is a novel therapy for rheumatoid arthritis (RA). The aim of this study was to measure various serum cytokines levels and to explore potential markers predictive of therapeutic efficacy of tofacitinib for RA patients. Methods. Thirty-two patients with RA were given tofacitinib (5 mg bid). Serum cytokines levels of Th1 (IFN-γ), Th2 (IL-6), Th17 (IL-17), Tregs (IL-35), and TNF-α were detected by enzyme-linked immunosorbent assays. Results. Disease activity was significantly decreased as early as week 4 after tofacitinib treatment. Serum IL-35 levels were significantly increased and serum levels of TNF-α, IL-17, IL-6, and IFN-γ were significantly reduced in response to tofacitinib since week 4. Conclusions. After treatment with tofacitinib, RA patients may benefit from monitoring of disease activity as early as week 4. IL-35 also might be a predictive indicator of the disease activity and drug efficacy. Meanwhile, tofacitinib might be CS-sparing in RA.
format Article
id doaj-art-9797b2ef6a3c4eb6acb7198995c527b5
institution Kabale University
issn 0962-9351
1466-1861
language English
publishDate 2019-01-01
publisher Wiley
record_format Article
series Mediators of Inflammation
spelling doaj-art-9797b2ef6a3c4eb6acb7198995c527b52025-02-03T01:10:13ZengWileyMediators of Inflammation0962-93511466-18612019-01-01201910.1155/2019/56174315617431Changes in Serum Cytokines May Predict Therapeutic Efficacy of Tofacitinib in Rheumatoid ArthritisYuxuan Li0Lin Yuan1Jie Yang2Yue Lei3Hui Zhang4Liping Xia5Hui Shen6Jing Lu7Department of Rheumatology and Immunology, The First Affiliated Hospital of China Medical University, 155 Nanjing North Street, Shenyang, Heping District 110001, ChinaDepartment of Rheumatology and Immunology, The First Affiliated Hospital of China Medical University, 155 Nanjing North Street, Shenyang, Heping District 110001, ChinaDepartment of Rheumatology and Immunology, The First Affiliated Hospital of China Medical University, 155 Nanjing North Street, Shenyang, Heping District 110001, ChinaDepartment of Rheumatology and Immunology, The First Affiliated Hospital of China Medical University, 155 Nanjing North Street, Shenyang, Heping District 110001, ChinaDepartment of Rheumatology and Immunology, The First Affiliated Hospital of China Medical University, 155 Nanjing North Street, Shenyang, Heping District 110001, ChinaDepartment of Rheumatology and Immunology, The First Affiliated Hospital of China Medical University, 155 Nanjing North Street, Shenyang, Heping District 110001, ChinaDepartment of Rheumatology and Immunology, The First Affiliated Hospital of China Medical University, 155 Nanjing North Street, Shenyang, Heping District 110001, ChinaDepartment of Rheumatology and Immunology, The First Affiliated Hospital of China Medical University, 155 Nanjing North Street, Shenyang, Heping District 110001, ChinaObjective. Tofacitinib is a novel therapy for rheumatoid arthritis (RA). The aim of this study was to measure various serum cytokines levels and to explore potential markers predictive of therapeutic efficacy of tofacitinib for RA patients. Methods. Thirty-two patients with RA were given tofacitinib (5 mg bid). Serum cytokines levels of Th1 (IFN-γ), Th2 (IL-6), Th17 (IL-17), Tregs (IL-35), and TNF-α were detected by enzyme-linked immunosorbent assays. Results. Disease activity was significantly decreased as early as week 4 after tofacitinib treatment. Serum IL-35 levels were significantly increased and serum levels of TNF-α, IL-17, IL-6, and IFN-γ were significantly reduced in response to tofacitinib since week 4. Conclusions. After treatment with tofacitinib, RA patients may benefit from monitoring of disease activity as early as week 4. IL-35 also might be a predictive indicator of the disease activity and drug efficacy. Meanwhile, tofacitinib might be CS-sparing in RA.http://dx.doi.org/10.1155/2019/5617431
spellingShingle Yuxuan Li
Lin Yuan
Jie Yang
Yue Lei
Hui Zhang
Liping Xia
Hui Shen
Jing Lu
Changes in Serum Cytokines May Predict Therapeutic Efficacy of Tofacitinib in Rheumatoid Arthritis
Mediators of Inflammation
title Changes in Serum Cytokines May Predict Therapeutic Efficacy of Tofacitinib in Rheumatoid Arthritis
title_full Changes in Serum Cytokines May Predict Therapeutic Efficacy of Tofacitinib in Rheumatoid Arthritis
title_fullStr Changes in Serum Cytokines May Predict Therapeutic Efficacy of Tofacitinib in Rheumatoid Arthritis
title_full_unstemmed Changes in Serum Cytokines May Predict Therapeutic Efficacy of Tofacitinib in Rheumatoid Arthritis
title_short Changes in Serum Cytokines May Predict Therapeutic Efficacy of Tofacitinib in Rheumatoid Arthritis
title_sort changes in serum cytokines may predict therapeutic efficacy of tofacitinib in rheumatoid arthritis
url http://dx.doi.org/10.1155/2019/5617431
work_keys_str_mv AT yuxuanli changesinserumcytokinesmaypredicttherapeuticefficacyoftofacitinibinrheumatoidarthritis
AT linyuan changesinserumcytokinesmaypredicttherapeuticefficacyoftofacitinibinrheumatoidarthritis
AT jieyang changesinserumcytokinesmaypredicttherapeuticefficacyoftofacitinibinrheumatoidarthritis
AT yuelei changesinserumcytokinesmaypredicttherapeuticefficacyoftofacitinibinrheumatoidarthritis
AT huizhang changesinserumcytokinesmaypredicttherapeuticefficacyoftofacitinibinrheumatoidarthritis
AT lipingxia changesinserumcytokinesmaypredicttherapeuticefficacyoftofacitinibinrheumatoidarthritis
AT huishen changesinserumcytokinesmaypredicttherapeuticefficacyoftofacitinibinrheumatoidarthritis
AT jinglu changesinserumcytokinesmaypredicttherapeuticefficacyoftofacitinibinrheumatoidarthritis